Compounders Research Compare

NEXGEL, Inc.(NXGL)

Medical - Instruments & Supplies · Langhorne, PA

$0.17-0.00 (-0.71%)

Delayed quote: Oct 6, 2026, 2:22 PM EDT

About NEXGEL, Inc.

NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.

Langhorne, PA

19 employees

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Brian J. Kieser

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:27:46.787Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:46.787Z.

Quote observation: 2026-10-06T18:22:45.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,430,697
Total debt · period ending 2026-06-30: 7,458,000
Cash · period ending 2026-06-30: 492,000
TTM operating income · period ending 2026-06-30: -5,402,000

FMP input reference: c1171bf84d9e01e227179f4391907e0b7edeaef3f5f58c6a2b8957218a297583

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NXGL EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

NXGL Competitors' EV/EBIT Ratio

NEXGEL, Inc.

Current

Market Cap

$1.43M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INVO Fertility, Inc.

Market Cap

$1.43M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curis, Inc.

Market Cap

$1.43M

EV/EBIT Ratio

N/A

TTM Avg

439.92x

3Y Avg

439.92x

5Y Avg

439.92x

Jupiter Neurosciences, Inc.

Market Cap

$1.39M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMGC Holdings Inc.

Market Cap

$1.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lakewood-Amedex Biotherapeutics, Inc.

Market Cap

$1.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Genprex, Inc.

Market Cap

$1.35M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.34M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Silo Pharma, Inc.

Market Cap

$1.60M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
NEXGEL, Inc. (NXGL)	$1.43M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.43M	N/A	N/A	N/A	N/A
Curis, Inc. (CRIS)vs ›	$1.43M	N/A	439.92x	439.92x	439.92x
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.39M	N/A	N/A	N/A	N/A
PMGC Holdings Inc. (ELAB)vs ›	$1.48M	N/A	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs ›	$1.48M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.36M	N/A	N/A	N/A	N/A
Genprex, Inc. (GNPX)vs ›	$1.35M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.34M	N/A	N/A	N/A	N/A
Silo Pharma, Inc. (SILO)vs ›	$1.60M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics